-
Cara Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Tuesday, March 1, 2022 - 7:04pm | 523Read More...Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31...
-
Cara Therapeutics Gains 9% After The FDA Removed A Clinical Hold On An Ongoing Trial
Wednesday, April 20, 2016 - 9:38am | 303Read More...Shares of Cara Therapeutics Inc (NASDAQ: CARA) were trading higher by more than 9 percent early Wednesday morning after the company confirmed the U.S. Food and Drug Administration (FDA) removed a hold on a clinical trial. Cara Therapeutics said it received notice from the FDA that the agency...
-
FDA Places Cara Therapeutics' Pain Trial On Clinical Hold, Shares Plunge 42%
Friday, February 26, 2016 - 8:35am | 237Read More...Cara Therapeutics Inc (NASDAQ: CARA), a clinical-stage bio-pharmaceutical company that focuses on the development of chemical entities to alleviate pain and pruritus, announced a business update after Thursday's market close. Cara Therapeutics said that the U.S. Food and Drug Administration has...
